Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer

Biomaterials

Volumn 61, Issue , 2015, Pages 33-40

  Rahimian, Sima ^a   Fransen, Marieke F ^b   Kleinovink, Jan Willem ^b   Amidi, Maryam ^a   Ossendorp, Ferry ^b   Hennink, Wim E ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AntiCD40; Cancer immunotherapy; CTLA4 blocking antibody; Immunomodulatory antibody; Incomplete Freund's adjuvant (IFA); Local delivery; PLHMGA; Sustained release

Indexed keywords

DISEASES; EMULSIFICATION; MAMMALS; TUMORS;

ANTICD40; CANCER IMMUNOTHERAPY; IMMUNOMODULATORY; INCOMPLETE FREUND'S ADJUVANT (IFA); LOCAL DELIVERY; PLHMGA; SUSTAINED RELEASE;

ANTIBODIES;

ANTIBODY; CD40 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FREUND ADJUVANT; IMMUNOGLOBULIN G; POLYMER; UNCLASSIFIED DRUG; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DELAYED RELEASE FORMULATION; IMMUNOLOGIC FACTOR; MICROCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL STIMULATION; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EMULSION; EVAPORATION; FEASIBILITY STUDY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; IMMUNOLOGY; MICROCAPSULE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; CAPSULES; CELL LINE, TUMOR; CELL SURVIVAL; CTLA-4 ANTIGEN; DELAYED-ACTION PREPARATIONS; DIFFUSION; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84939151920     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.043     Document Type: Article

References (59)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342:1432-1433.
2. Weir G.M., Liwski R.S., Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers 2011, 3:3114-3142.
3. Dimberu P.M., Leonhardt R.M. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J. Biol. Med. 2011, 84:371-380.
4. Vatsan R.S., Bross P.F., Liu K., Theoret M., De Claro A.R., Lu J., et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J. Immunother. Cancer 2013, 1. 5-5.
5. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
6. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
7. Peggs K.S., Quezada S.A., Allison J.P. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 2009, 157:9-19.
8. Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006, 90:297-339.
9. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
10. Brahmer J.R., Pardoll D.M. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol. Res. 2013, 1:85-91.
11. Todryk S., Tutt A., Green M., Smallwood J., Halanek N., Dalgleish A., et al. CD40 ligation for immunotherapy of solid tumours. J. Immunol. Methods 2001, 248:139-147.
12. Rudd C.E. The reverse stop-signal model for CTLA4 function. Nat. Rev. Immunol. 2008, 8:153-160.
13. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of t-cells to stimulation. J. Exp. Med. 1995, 182:459-465.
14. Ascierto P.A., Marincola F.M., Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 2011, 9. 196-5876-9-196.
15. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3:611-618.
16. Quezada S.A., Peggs K.S., Simpson T.R., Allison J.P. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 2011, 241:104-118.
17. Sandin L.C., Eriksson F., Ellmark P., Loskog A.S.I., Totterman T.H., Mangsbo S.M. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunol 2014, 3. e27614.
18. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013, 13:5.
19. Camacho L.H. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Exp. Opin. Investig. Drugs 2008, 17:371-385.
20. Lens M., Ferrucci P.F., Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings. Recent Pat. Anticancer Drug Discov. 2008, 3:105-113.
21. Morel Y., Truneh A., Sweet R., Olive D., Costello R. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 2001, 167:2479-2486.
22. van Mierlo G., den Boer A., Medema J., van der Voort E., Fransen M., Offringa R., et al. CD40 stimulation leads to effective therapy of CD40(-)tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5561-5566.
23. Schoenberger S., Toes R., van der Voort E., Offringa R., Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
24. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
25. Attia P., Phan G., Maker A., Robinson M., Quezado M., Yang J., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23:6043-6053.
26. Fransen M.F., Arens R., Melief C.J.M. Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. Int. J. Cancer 2013, 132:1971-1976.
27. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 2013, 19:1035-1043.
28. Maker A., Yang J., Sherry R., Topalian S., Kannula U., Royal R., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 2006, 29:455-463.
29. Baldo B.A. Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses. Oncoimmunol 2013, 2.
30. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005, 23:741-750.
31. Fransen M.F., van der Sluis T.C., Ossendorp F., Arens R., Melief C.J.M. Controlled local delivery of CTLA-4 blocking antibody induces cd8(+) t-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 2013, 19:5381-5389.
32. Fransen M.F., Sluijter M., Morreau H., Arens R., Melief C.J. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 2011, 17:2270-2280.
33. Aucouturier J., Ascarateil S., O'Neill S. A review of some cancer clinical trials with montanide ISA 51 vaccine adjuvant. J. Immunother. 2003, 26:S45-S46.
34. Graham B.S., McElrath M.J., Keefer M.C., Rybczyk K., Berger D., Weinhold K.J., et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010, 5:e11995.
35. Ghassemi A.H., van Steenbergen M.J., Barendregt A., Talsma H., Kok R.J., van Nostrum C.F., et al. Controlled release of octreotide and assessment of peptide acylation from poly(d,l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres. Pharm. Res. 2012, 29:110-120.
36. Liu Y., Ghassemi A.H., Hennink W.E., Schwendeman S.P. The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation. Biomaterials 2012, 33:7584-7593.
37. Ghassemi A.H., van Steenbergen M.J., Talsma H., van Nostrum C.F., Jiskoot W., Crommelin D.J.A., et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid). J. Control Release 2009, 138:57-63.
38. Samadi N., van Nostrum C.F., Vermonden T., Amidi M., Hennink W.E. Mechanistic studies on the degradation and protein release characteristics of poly(lactic-co-glycolic-co-hydroxymethylglycolic acid) nanospheres. Biomacromolecules 2013, 14:1044-1053.
39. Kazazi-Hyseni F., Zandstra J., Popa E., Goldschmeding R., Lathuile A., Veldhuis G., et al. Biocompatibility of poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. Int. J. Pharm. 2015, 482:99-109.
40. Rahimian S., Kleinovink J.W., Fransen M.F., Mezzanotte L., Gold H., Wisse P., et al. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response. Biomaterials 2015, 37:469-477.
41. Doshi N., Mitragotri S. Macrophages recognize size and shape of their targets. PloS One 2010, 5:e10051.
42. Leemhuis M., van Nostrum C., Kruijtzer J., Zhong Z., ten Breteler M., Dijkstra P., et al. Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: Toward hydrophilic polyesters with pendant hydroxyl groups. Macromolecules 2006, 39:3500-3508.
43. Ghassemi A.H., van Steenbergen M.J., Talsma H., van Nostrum C.F., Crommelin D.J.A., Hennink W.E. Hydrophilic polyester microspheres: effect of molecular weight and copolymer composition on release of BSA. Pharm. Res. 2010, 27:2008-2017.
44. Sah H. A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. J. Pharm. Sci. 1997, 86:1315-1318.
45. Rolink A., Melchers F., Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996, 5:319-330.
46. Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 1998, 58:1469-1477.
47. Champion J.A., Walker A., Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 2008, 25:1815-1821.
48. Giteau A., Venier-Julienne M.C., Aubert-Pouessel A., Benoit J.P. How to achieve sustained and complete protein release from PLGA-based microparticles?. Int. J. Pharm. 2008, 350:14-26.
49. Sinha V., Trehan A. Biodegradable microspheres for protein delivery. J. Control Release 2003, 90:261-280.
50. Allison S.D. Analysis of initial burst in PLGA microparticles. Exp. Opin. Drug Deliv. 2008, 5:615-628.
51. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control Release 2001, 73:121-136.
52. Yang Y., Chung T., Bai X., Chan W. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem. Eng. Sci. 2000, 55:2223-2236.
53. Yang Y., Chung T. Ping Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001, 22:231-241.
54. Leemhuis M., Kruijtzer J.A.W., van Nostrurn C.F., Hennink W.E. In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s. Biomacromolecules 2007, 8:2943-2949.
55. Sharon E., Streicher H., Goncalves P., Chen H.X. Immune checkpoints in cancer clinical trials. Chin. J. Cancer 2014, 33:434-444.
56. Fransen M.F., Ossendorp F., Arens R., Melief C.J.M. Local immunomodulation for cancer therapy Providing treatment where needed. Oncoimmunol 2013, 2:e26493.
57. Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 24(Suppl 2). S2-S44-5.
58. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20(Suppl 3):S56-S64.
59. Fransen M.F., Cordfunke R.A., Sluijter M., van Steenbergen M.J., Drijfhout J.W., Ossendorp F., et al. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine 2014, 32:1654-1660.